First Western Trust Bank Has $843,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

First Western Trust Bank decreased its stake in Eli Lilly and Company (NYSE:LLY) by 11.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,798 shares of the company’s stock after selling 243 shares during the quarter. First Western Trust Bank’s holdings in Eli Lilly and Company were worth $843,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Silicon Valley Capital Partners purchased a new stake in Eli Lilly and Company in the 1st quarter worth about $25,000. Laffer Tengler Investments purchased a new stake in Eli Lilly and Company in the 1st quarter worth about $33,000. Raleigh Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 156.4% during the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after purchasing an additional 61 shares in the last quarter. Activest Wealth Management purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $40,000. Finally, Riggs Asset Managment Co. Inc. raised its stake in shares of Eli Lilly and Company by 50.4% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 179 shares of the company’s stock worth $61,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $5.51 during midday trading on Monday, hitting $597.22. 1,494,823 shares of the company were exchanged, compared to its average volume of 3,097,466. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. The firm has a market cap of $566.95 billion, a P/E ratio of 107.54, a PEG ratio of 3.57 and a beta of 0.33. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $629.97. The firm has a 50 day simple moving average of $577.98 and a 200-day simple moving average of $509.95.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $1.13 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $4.52 annualized dividend and a yield of 0.76%. Eli Lilly and Company’s payout ratio is 81.88%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 670 shares of Eli Lilly and Company stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the transaction, the chief accounting officer now owns 4,708 shares in the company, valued at approximately $2,688,738.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Donald A. Zakrowski sold 670 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the completion of the sale, the chief accounting officer now owns 4,708 shares in the company, valued at $2,688,738.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 1,307 shares of the business’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $555.69, for a total value of $726,286.83. Following the sale, the insider now owns 100,397,503 shares of the company’s stock, valued at approximately $55,789,888,442.07. The disclosure for this sale can be found here. In the last quarter, insiders sold 535,538 shares of company stock worth $20,881,299,452. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. BMO Capital Markets raised their price target on Eli Lilly and Company from $565.00 to $633.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Morgan Stanley raised their price objective on Eli Lilly and Company from $673.00 to $722.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a research note on Wednesday, August 9th. Truist Financial raised their price objective on Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $557.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.